Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Vaccine protects against B1.1.7 variant
Abstract
Acknowledgments
Supplementary Material
Summary
Resources
References and Notes
(0)eLetters
eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter.
Log In to Submit a ResponseNo eLetters have been published for this article yet.
Information & Authors
Information
Published In
12 March 2021
Copyright
Article versions
Submission history
Acknowledgments
Authors
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Cite as
- Alexander Muik et al.
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage, Current Topics in SARS-CoV-2/COVID-19 - Two Years After, (2023).https://doi.org/10.5772/intechopen.107842
- SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic, Vaccines, 11, 3, (682), (2023).https://doi.org/10.3390/vaccines11030682
- Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences, Medicina, 59, 3, (507), (2023).https://doi.org/10.3390/medicina59030507
- Validation and Establishment of the SARS-CoV-2 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction Neutralization Test, Microbiology Spectrum, 11, 1, (2023).https://doi.org/10.1128/spectrum.03789-22
- A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus, Science Advances, 9, 25, (2023)./doi/10.1126/sciadv.abo4100
- Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2, Human Vaccines & Immunotherapeutics, 19, 1, (2023).https://doi.org/10.1080/21645515.2023.2174755
- From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis, Communications Biology, 6, 1, (2023).https://doi.org/10.1038/s42003-023-04589-5
- Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5, Cell Discovery, 9, 1, (2023).https://doi.org/10.1038/s41421-022-00509-9
- Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization, Molecular Therapy, (2023).https://doi.org/10.1016/j.ymthe.2023.02.012
- Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2, International Immunopharmacology, 117, (109968), (2023).https://doi.org/10.1016/j.intimp.2023.109968
- See more
View Options
View options
PDF format
Download this article as a PDF file
Download PDFCheck Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
More options
Register for free to read this article
As a service to the community, this article is available for free. Login or register for free to read this article.
Buy a single issue of Science for just $15 USD.
RE: Neutralizing the Impact of the UK COVID-19 Lineage
The informative and beneficial research report by a team of medical experts on neutralizing the impact of the UK COVID-19 lineage using vaccine-elicited human sera that were obtained 3 weeks after the booster shot of a two-shot vaccine.
The observed decrease in neutralization was clearer for participants aged under 55 years, and the vaccine was found to provide significant protection against the UK variant in a comparison with the original wild-type coronavirus (COVID-19).
Although the mutated UK lineage seems to have dominated global COVID-19 infection, it would also be useful for public healthcare policy if the vaccines were tested against the other mutated lineages that have emerged in South Africa, Brazil, USA, India, and Russia.
Updating the data beyond 14 November 2020 would accommodate the production and distribution of a range of vaccines, including single-shot vaccines, and the emergence of escaped mutants, such that using vaccine-elicited human sera 3-4 and 12 weeks after the single shot, could strengthen the impressive and promising findings of the research outcomes.
Maintaining the safety and efficacy of any vaccines arising from these observed outcomes is essential, as would any clarification regarding the as yet unknown temporal durability of protection arising from the vaccines.
RE: Neutralization of Antibodies Against Escaped Mutants
It is known that there have been escaped mutants of the original wild-type coronavirus (COVID-19) in the UK, South Africa, Brazil, and possibly also the USA, that are more highly transmissible and infectious.
The UK is presently grappling with both the home-grown mutated strain, as well as the on from South Africa.
The neutralizing antibodies may fail to recognize the UK and other variants because of the associated large number of amino acid changes, so human immune sera were used to restrict the mutations while preserving the biological neutralization.
As young and older adults were tested, and found not to be different statistically, using a wider range of age cohorts and gender against mild, medium, and severe mutated variants would be informative.
Whether the neutralization would be effective as mediated protection against the other untested strains remains to be seen.